🇺🇸 FDA
Patent

US 11787839

Targeting α2δ-1-bound glutamate receptors for treating diseases and disorders

granted A61KA61K31/485A61K31/515

Quick answer

US patent 11787839 (Targeting α2δ-1-bound glutamate receptors for treating diseases and disorders) held by The Board of Regents of the University of Texas System expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/485, A61K31/515, A61K31/5513, A61K38/00